Placeholder Banner

BIO Comments to HHS on Medicare Prescription Payment Plan: Draft Part Two Guidance on Implementation of Section 1860D-2 of the Social Security Act for 2025

March 16, 2024

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ (CMS’s/the Agency’s) Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025, and Solicitation of Comments.

Download Full Comments Below
BIO Comments to HHS on Medicare Prescription Payment Plan: Draft Part Two Guidance on Implementation of Section 1860D-2 of the Social Security Act for 2025
Discover More
In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…
In response to the 340B Request for Information issued by the Senate 340B Bipartisan Working Group, BIO submits detailed comments.